Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website starting early August, the U.S. drugmaker said on Monday. With the addition ...

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

Eli Lilly is reducing the price of the highest doses of its popular drug Zepbound for folks who aren't using insurance.

Novo Nordisk, the maker of Ozempic and Wegovy weight-loss drugs, just regained the title as Europe’s most valuable company ...

We have recently begun acquiring a new position in Novo Nordisk. Click here for our investment thesis on NVO stock.

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...